Lexeo Therapeutics, Inc. Intellectual Property Contracts & Agreements
10 Contracts & Agreements
- License Agreements (10 contracts)
- Amendment No. 3, dated February 11, 2024, to the First License Agreement, dated May 28, 2020, by and between LEXEO Therapeutics, Inc. and Cornell University (as amended by... (Filed With SEC on April 9, 2024)
- License Agreement, dated January 19, 2021, between Adverum Biotechnologies, Inc. and LEXEO Therapeutics, Inc., as amended by the First Amendment, dated February 28, 2022 (Filed With SEC on September 29, 2023)
- Amendment No. 2, dated September 28, 2022, to the First License Agreement, dated May 28, 2020, by and between LEXEO Therapeutics, Inc. and Cornell University (as amended by... (Filed With SEC on September 29, 2023)
- Amendment No. 1, dated July 4, 2022, to the First License Agreement, dated May 28, 2020, by and between LEXEO Therapeutics, Inc. and Cornell University and Amendment No. 2, dated... (Filed With SEC on September 29, 2023)
- Amendment No. 1, dated January 13, 2022, to the Second License Agreement, dated May 28, 2020, by and between LEXEO Therapeutics, Inc. and Cornell University (Filed With SEC on September 29, 2023)
- Second License Agreement, dated May 28, 2020, between LEXEO Therapeutics, LLC and Cornell University (Filed With SEC on September 29, 2023)
- First License Agreement, dated May 28, 2020, between LEXEO Therapeutics, LLC and Cornell University (Filed With SEC on September 29, 2023)
- License Agreement, dated August 6, 2020, by and between Stelios Therapeutics, Inc. and the Regents of the University of California (Filed With SEC on September 29, 2023)
- License Agreement, dated April 23, 2020, by and between Stelios Therapeutics, Inc. (as successor-in-interest to ARVC Therapeutics, Inc.) and the Regents of the University of... (Filed With SEC on September 29, 2023)
- License Agreement, dated October 4, 2021, by and between LEXEO Therapeutics, Inc. and the Regents of the University of California (Filed With SEC on September 29, 2023)